Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunoth...
Q1 2026
May 12, 2026
FY 2025
Mar 5, 2026
Q4 2025
Q3 2025
Nov 17, 2025
Q2 2025
Aug 13, 2025